1-((1R)-1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol | 847937-51-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-((1R)-1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol
• 英文别名: 1-[(1R)-1-(4-methoxyphenyl)-2-(methylamino)ethyl]cyclohexan-1-ol
• CAS: 847937-51-3
• 化学式: C₁₆H₂₅NO₂
• 分子量: 263.37
• InChiKey: MKAFOJAJJMUXLW-HNNXBMFYSA-N

物化性质

• 沸点：
  396.2±22.0 °C(Predicted)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20150299102A1

  公开（公告）日：2015-10-22

  Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

  本文揭示了制备(-)-文拉法辛衍生物的方法和包含该衍生物的组合物。还揭示了治疗和预防疾病和疾病的方法，包括但不限于情感障碍，如抑郁症，双相和躁狂障碍，注意力缺陷障碍，注意力缺陷过动障碍，帕金森病，癫痫，脑功能障碍，肥胖和体重增加，失禁，痴呆及相关疾病。
• Extended release pharmaceutical dosage form
  申请人：Wyeth

  公开号：EP1523979A1

  公开（公告）日：2005-04-20

  This invention relates to novel extended release pharmaceutical dosage forms for orally delivering drugs to mammals, e.g., humans. More particularly, this invention concerns novel dosage forms of water soluble drugs such as venlafaxine, enantiomeric (R or S) forms of venlafaxine, metabolites of venlafaxine such as O-desmethyl venlafaxine (ODV) or enantiomeric (R or S) forms of said metabolites which dosage forms have an extended release profile when taken orally. This invention also provides processes for preparing such dosage forms and methods of using them.

  本发明涉及向哺乳动物（如人类）口服给药的新型缓释药物剂型。更具体地说，本发明涉及水溶性药物如文拉法辛、文拉法辛的对映体（R或S）形式、文拉法辛的代谢物如O-去甲基文拉法辛（ODV）或上述代谢物的对映体（R或S）形式的新型剂型，这些剂型在口服时具有缓释特性。本发明还提供了制备此类剂型的工艺和使用方法。
• Enantiomers of N-desmethyl venlafaxine
  申请人：American Home Products Corporation

  公开号：US20020035158A1

  公开（公告）日：2002-03-21

  The present invention provides enantiomers of N-Desmethyl venlafaxine, as well as their use in pharmaceutical compositions and medically useful treatments, particularly including central nervous system uses.

  本发明提供了 N-去甲基文拉法辛的对映体，以及它们在药物组合物和医学治疗中的用途，特别是包括中枢神经系统用途。
• EXTENDED RELEASE PHARMACEUTICAL DOSAGE FORM
  申请人：Wyeth

  公开号：EP1675575A2

  公开（公告）日：2006-07-05
• Enantiomers of N-Desmethyl venlafaxine
  申请人：Yardley P. John

  公开号：US20070117870A1

  公开（公告）日：2007-05-24

  The present invention provides enantiomers of N-Desmethyl venlafaxine, as well as their use in pharmaceutical compositions and medically useful treatments, particularly including central nervous system uses.